Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda (RMDA) Key Statistics
26 reported figures for Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda — valuation multiples, the latest fiscal year's income statement, balance-sheet totals, growth rates and technical readings. Figures with no reported value are omitted rather than shown as zero.
Valuation
- Market cap
- EGP 12.81B
- P/E (trailing)
- 37.07
- P/B
- 4.38
- Dividend yield
- 0.48%
Income (latest fiscal year)
- Revenue
- EGP 4.1B
- Net income
- EGP 268.61M
- EBITDA
- EGP 1.03B
- Free cash flow
- EGP -199.57M
- Profit margin
- 6.56%
Balance sheet
- Total assets
- EGP 5.34B
- Total debt
- EGP 2.41B
- Book value
- EGP 2.21B
Growth
- Revenue growth
- 47.94%
- Profit growth
- -26.17%
- EPS growth
- -26.87%
Per share
- EPS (fiscal year)
- 0.13
- Book value per share
- 1.43
- Dividend per share
- 0.03
- Return on equity
- 12.75%
- Return on assets
- 5.57%
Technical
- RSI (14)
- 56.4
- 50-day moving average
- EGP 5.72
- 200-day moving average
- EGP 4.46
- Beta (1Y)
- 0.47
Shares
- Shares outstanding
- 2.03B
- Free float
- 67.68%
Source: company disclosures to the Egyptian Exchange via TradingView. Fiscal-year figures are as last reported; technical readings refresh with market data.